GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Corcept Therapeutics
Corcept Therapeutics specializes in treating diseases related to the hormone cortisol. Its stock price is largely dependent on sales of its flagship drug, Korlym, and its success in expanding its use. The chart shows the risks and opportunities for the company's single product.
Share prices of companies in the market segment - Pharma metabolism
Corcept Therapeutics operates in the pharmaceutical segment, specializing in drugs that regulate the hormone cortisol. We classify it in the Metabolic Pharmaceuticals sector. The chart below reflects the dynamics of this entire innovative, yet risky, segment.
Broad Market Index - GURU.Markets
Corcept Therapeutics is a biopharmaceutical company focused on developing drugs that modulate cortisol for the treatment of metabolic diseases and oncology. It is a component of the GURU.Markets index, and the chart below shows how its stock compares to the broader market.
Change in the price of a company, segment, and market as a whole per day
CORT - Daily change in the company's share price Corcept Therapeutics
Shares of Corcept Therapeutics, a company developing drugs for metabolic disorders, exhibit the high volatility typical of biotech. Daily price changes reflect sensitivity to clinical trial news. This metric is an important component of complex formulas on System.GURU.Markets for pharmaceutical risk analysis.
Daily change in the price of a set of shares in a market segment - Pharma metabolism
Corcept Therapeutics Incorporated is a pharmaceutical company. This chart highlights the sector's high volatility. Comparing this to CORT, whose success hinges on a single drug for a rare disease, helps to understand its high concentration risks.
Daily change in the price of a broad market stock, index - GURU.Markets
Corcept Therapeutics is a biopharmaceutical company specializing in cortisol-modulating drugs for the treatment of metabolic diseases and oncology. The chart below shows volatility in the biotech sector, providing context for analyzing Corcept stock.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Corcept Therapeutics
Corcept is a biotech company specializing in the treatment of cortisol-related diseases. Its year-over-year performance reflects both the commercial success of its drugs and investor confidence in its R&D platform, which is focused on new breakthrough drugs.
Annual dynamics of market capitalization of the market segment - Pharma metabolism
Corcept Therapeutics Incorporated is a biopharmaceutical company specializing in the development of drugs that modulate cortisol. Its success depends on the commercialization of its key drug and the expansion of its use. The chart below shows how its unique scientific niche influences its performance in the pharmaceutical sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Corcept Therapeutics is a pharmaceutical company whose future depends on the sales of its drugs and the success of its research. Its stock price is completely disconnected from economic cycles. The chart reflects biotech events—news about clinical trials and regulatory decisions—rather than macroeconomic data.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Corcept Therapeutics
The value of Corcept Therapeutics, a biopharmaceutical company, depends on the success of its drugs. The monthly fluctuations on the chart reflect sales data for its lead drug for Cushing's syndrome and, more importantly, news about clinical trials that could expand its use in oncology.
Monthly dynamics of market capitalization of the market segment - Pharma metabolism
This chart reflects the dynamics of the biotech sector. For Corcept, with its focus on treating cortisol-related disorders, it's the backdrop. Its movements show how the company, with an approved drug, is protecting its niche and developing new drugs.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Corcept Therapeutics is a biopharmaceutical company specializing in drugs that modulate cortisol for the treatment of metabolic diseases and oncology. The chart below shows overall market sentiment. Corcept's performance is almost entirely dependent on the success of its drugs, not on general economic trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Corcept Therapeutics
For Corcept Therapeutics, a biopharmaceutical company, weekly stock performance is a barometer of clinical trial news. Shares are sensitive to the publication of trial data, regulatory decisions, and announcements from competitors in the metabolic disease field.
Weekly dynamics of market capitalization of the market segment - Pharma metabolism
Corcept Therapeutics operates in the volatile biopharmaceutical sector, where investor sentiment often influences all players. M&A news or general regulatory changes can lift or derail the entire segment. The chart will show whether CORT is moving with the industry or whether its drug development successes are creating a unique story of their own.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
As a biotech company, Corcept Therapeutics often ignores broader market trends. Its fate depends not on GDP or inflation, but on clinical trial results and FDA decisions. The chart below clearly demonstrates how CORT shares can rise or fall on news releases while the overall market remains stagnant.
Market capitalization of the company, segment and market as a whole
CORT - Market capitalization of the company Corcept Therapeutics
Corcept Therapeutics' market capitalization tells the story of the fight against rare metabolic diseases. The chart reflects investor expectations for the success of its drugs targeting hormonal disorders. Every movement on the chart reflects the market's assessment of the company's potential in this niche but vital area of pharmacology.
CORT - Share of the company's market capitalization Corcept Therapeutics within the market segment - Pharma metabolism
Corcept Therapeutics develops drugs to treat metabolic and oncological diseases associated with the hormone cortisol. Its market share in its niche pharmaceutical segment is an indicator of the uniqueness of its scientific platform. The chart below reflects how the market perceives the potential of its drugs and its competitive position.
Market capitalization of the market segment - Pharma metabolism
Corcept Therapeutics develops drugs to treat metabolic and oncological diseases. The chart below shows the total value of the pharmaceutical sector focused on metabolism. This represents a capitalization of hopes for breakthroughs in the treatment of diseases such as diabetes and obesity.
Market capitalization of all companies included in a broad market index - GURU.Markets
Corcept Therapeutics develops drugs to treat diseases associated with the hormone cortisol. The company's market cap is a bet on its ability to solve complex metabolic problems. On a global market scale, its value reflects the value investors see in targeted therapy for rare and difficult-to-treat endocrine disorders.
Book value capitalization of the company, segment and market as a whole
CORT - Book value capitalization of the company Corcept Therapeutics
Corcept Therapeutics' book value is capital for scientific breakthroughs. It consists not of manufacturing plants, but of intellectual property (drug patents), cash for clinical trials, and laboratory equipment. The chart below shows how successful drug development and sales have enabled the company to accumulate this financial foundation.
CORT - Share of the company's book capitalization Corcept Therapeutics within the market segment - Pharma metabolism
Corcept Therapeutics' success is based on its research laboratories and drug manufacturing facilities. These research centers are its main tangible asset. The chart shows the company's control over the physical infrastructure in the metabolic drug segment.
Market segment balance sheet capitalization - Pharma metabolism
Below you can see the overall book value of the pharmaceutical sector. Against this backdrop, Corcept Therapeutics looks like a lightweight, innovative company. Its business is built not on giant factories, but on intellectual property—drug patents. Its modest book value contrasts with the high scientific value of its developments.
Book value of all companies included in the broad market index - GURU.Markets
Corcept Therapeutics' assets aren't factories, but intellectual property: drug patents and clinical trial results. Their book value represents investments in science that will eventually become real drugs. Compared to a chart of all tangible market assets, Corcept demonstrates how intangible ideas can carry enormous weight.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Corcept Therapeutics
Corcept's book value is its cash reserves and patents. Its market capitalization is an estimate of the potential of its drugs to treat cortisol-related conditions. The chart shows how much higher investors value scientific breakthroughs and future sales than current assets and research costs.
Market to book capitalization ratio in a market segment - Pharma metabolism
Corcept Therapeutics develops drugs to treat metabolic diseases. Its value comes from its research and patents. The chart clearly shows the significant premium the market places on its intellectual property over its physical assets, reflecting the expectations for the success of its drugs.
Market to book capitalization ratio for the market as a whole
Corcept Therapeutics develops drugs to treat metabolic, oncological, and psychiatric diseases by modulating the hormone cortisol. The company's main assets are its patents and clinical trial results. This chart helps explain why biotech companies can have enormous market capitalizations with modest book values.
Debts of the company, segment and market as a whole
CORT - Company debts Corcept Therapeutics
Corcept Therapeutics, a biopharmaceutical company, has a debt strategy focused on funding clinical trials. This chart shows how the company raises funds to develop and commercialize new drugs. In the biotech world, where R&D requires massive investments, debt capital is the bridge between a scientific idea and a commercial product.
Market segment debts - Pharma metabolism
Corcept Therapeutics develops drugs to treat metabolic and oncological diseases associated with the hormone cortisol. Pharmaceutical research is a lengthy and expensive process with unpredictable outcomes. This chart provides insight into how the company funds its clinical trials and the sustainability of its financial model.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Corcept Therapeutics
Corcept Therapeutics develops drugs to treat metabolic and oncological diseases, which require lengthy and expensive clinical trials. This chart shows the company's financial policy. It reflects whether Corcept leverages R&D or relies on revenue from existing products, indicating its maturity and risk appetite.
Market segment debt to market segment book capitalization - Pharma metabolism
Corcept Therapeutics focuses on developing drugs to treat metabolic and oncological diseases. This chart shows the dynamics of debt in their pharmaceutical segment. This allows investors to understand whether Corcept finances its expensive clinical trials with debt or relies on equity, and how this compares to the industry.
Debt to book value of all companies in the market
Corcept Therapeutics is a biopharmaceutical company whose success depends on clinical trials. The chart reflects the overall market leverage. It allows us to assess the extent to which Corcept's financial strategy is independent of market sentiment. Does the company continue to invest and raise capital for its research, even if the overall market is in risk-off mode?
P/E of the company, segment and market as a whole
P/E - Corcept Therapeutics
This chart shows how the market values the pharmaceutical company Corcept Therapeutics. Its P/E is heavily dependent on the success of its lead drug for Cushing's syndrome and the prospects for its broader use. A high P/E indicates investor confidence in sales growth and new developments, while a low P/E may reflect concerns about patent expirations.
P/E of the market segment - Pharma metabolism
Here's the average P/E for pharmaceutical companies specializing in metabolic diseases. For Corcept Therapeutics, this is key context. Comparing its P/E to this average shows how highly investors value its lead drug and its development potential compared to other players in this niche therapeutic area.
P/E of the market as a whole
Corcept Therapeutics develops drugs to treat metabolic and oncological diseases caused by the hormone cortisol. Like many biotechs, its valuation is heavily dependent on the success of clinical trials. This chart of common market multiples helps us understand how high investor expectations for Corcept's scientific potential are compared to the overall market.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Corcept Therapeutics
Corcept Therapeutics specializes in developing drugs to treat metabolic and oncological diseases associated with the hormone cortisol. The company's future profitability depends almost entirely on the success of its key drug and development pipeline. This chart reflects market expectations regarding the expansion of drug indications and clinical trial results.
%20P%2FE%20Corcept%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Corcept-Therapeutics&v=1772623083760 "Chart of the company's future (projected) P/E Corcept Therapeutics")
Future (projected) P/E of the market segment - Pharma metabolism
Corcept Therapeutics develops drugs for the treatment of severe metabolic and oncological diseases by targeting the hormone cortisol. This is a highly specialized and research-intensive niche. The data here reflects average profitability forecasts for the pharmaceutical sector, allowing us to assess the market's confidence in the commercial success of Corcept's unique developments.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-metabolism&v=1772623083840 "Future (projected) P/E graph of the market segment - Pharma metabolism")
Future (projected) P/E of the market as a whole
Corcept Therapeutics develops drugs to treat metabolic and oncological diseases associated with the hormone cortisol. For the biotech company, the overall market backdrop, as seen in this chart, is crucial. High investor optimism facilitates raising capital for expensive clinical trials, allowing the company to bring life-saving drugs to market more quickly.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772623084048 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Corcept Therapeutics
Corcept Therapeutics focuses on developing drugs to treat metabolic and oncological diseases associated with the hormone cortisol. The dynamics of this graph reflect the commercial success of its key drugs. Profit growth is directly related to sales volumes and approvals for new indications, demonstrating the company's potential in its narrow pharmaceutical niche.
Profit of companies in the market segment - Pharma metabolism
Corcept Therapeutics develops drugs to treat metabolic and oncological diseases associated with the hormone cortisol. The company's success depends on clinical trial results and regulatory approval. This chart shows the overall profitability of niche pharmaceutical companies, where breakthroughs in rare disease treatments can lead to explosive revenue growth.
Overall market profit
Corcept Therapeutics develops drugs to treat metabolic and oncological diseases associated with the hormone cortisol. As a biotech company with a narrow focus, its success depends more on clinical trial results than on general economic trends. It's an interesting example of a business that can grow despite market cycles.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Corcept Therapeutics
Corcept Therapeutics develops drugs to treat metabolic and oncological diseases caused by the hormone cortisol. The company's revenue forecast depends on the success of its key drug and the development of new drugs. This chart reflects analyst expectations for sales growth of existing products and the potential of Corcept's endocrinology pipeline.
%20profit%20of%20the%20company%20Corcept%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Corcept-Therapeutics&v=1772623084387 "Graph of future (projected) profit of the company Corcept Therapeutics")
Future (predicted) profit of companies in the market segment - Pharma metabolism
Corcept Therapeutics develops drugs to treat diseases associated with the hormone cortisol. The company focuses on complex metabolic and oncology niches. This chart shows overall profitability forecasts for the pharmaceutical sector. It allows one to assess the success of Corcept's strategy in its narrow specialization against the backdrop of overall industry trends.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-metabolism&v=1772623084464 "Graph of future (predicted) profits of companies in a market segment - Pharma metabolism")
Future (predicted) profit of the market as a whole
Corcept Therapeutics develops drugs to treat severe metabolic diseases. The company's success depends on investments in biotechnology and overall healthcare spending. This chart, reflecting confidence in the economic future, indirectly indicates the market's willingness to finance innovative developments. A positive outlook creates a favorable environment for raising capital and commercializing new drugs.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772623084511 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Corcept Therapeutics
Corcept Therapeutics develops drugs to treat metabolic and oncological diseases caused by the hormone cortisol. The company's revenue depends almost entirely on the success of its key drug. The chart illustrates how the market values these sales, which indicates investor confidence in current demand and the potential of the company's future developments.
P/S market segment - Pharma metabolism
Corcept Therapeutics is a pharmaceutical company specializing in the development of drugs that modulate cortisol for the treatment of metabolic, oncological, and psychiatric diseases. Its revenue depends on the success of its drug, Korlym. This chart shows how investors view Corcept's niche specialization compared to other pharmaceutical companies.
P/S of the market as a whole
Corcept Therapeutics develops drugs to treat metabolic and oncological diseases caused by the hormone cortisol. The company's revenue depends on the success of its key drug and clinical trials. This chart helps assess the premium the market is willing to place on the revenue of a highly specialized biotech company compared to the average.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Corcept Therapeutics
Corcept Therapeutics develops drugs to treat severe metabolic and oncological diseases. This chart shows how investors assess the company's potential future revenue. This trend is closely tied to sales forecasts for its existing drugs and expectations for the successful launch of new developments in its pipeline.
%20P%2FS%20Corcept%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Corcept-Therapeutics&v=1772623084639 "The graph of the company's future (projected) P/S Corcept Therapeutics")
Future (projected) P/S of the market segment - Pharma metabolism
Corcept Therapeutics is focused on developing cortisol-regulating drugs for the treatment of rare diseases. This chart shows the company's future revenue expectations relative to its industry. It allows one to assess how highly the market values the potential of Corcept's current and future drugs in their highly specialized medical niche.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-metabolism&v=1772623084709 "Future (projected) P/S market segment graph - Pharma metabolism")
Future (projected) P/S of the market as a whole
Investor optimism about future revenues depends on innovation in the pharmaceutical industry. Corcept Therapeutics, developing drugs to treat metabolic and oncological diseases, is part of this innovation process. The success of their research and the launch of new drugs to market inspire confidence in the industry's ability to solve complex medical problems and generate revenue.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772623084725 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Corcept Therapeutics
Corcept Therapeutics is focused on developing drugs that regulate the hormone cortisol. The company's primary revenue comes from sales of Korlym, a drug for the treatment of Cushing's syndrome. The revenue dynamics in this graph are almost entirely dependent on sales of this key product, demonstrating the company's success in treating this rare and severe disease.
Sales of companies in the market segment - Pharma metabolism
Corcept Therapeutics develops drugs to treat severe metabolic and oncological diseases associated with the hormone cortisol. This chart shows total revenue in the metabolism-focused pharmaceutical segment. It illustrates the market size and the need for new treatments, where Corcept is pursuing its unique therapeutic niche.
Overall market sales
Corcept Therapeutics is a biopharmaceutical company focused on developing cortisol-regulating drugs for the treatment of metabolic diseases and oncology. Its commercial success depends on the healthcare system and patient affordability. This chart of overall economic health helps assess the availability of healthcare funding and the system's ability to cover expensive drugs.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Corcept Therapeutics
Corcept Therapeutics develops drugs to treat metabolic and oncological diseases associated with the hormone cortisol. Its financial success depends on sales of its flagship drug and clinical trial results. This chart shows analysts' future revenue expectations based on market growth forecasts and the potential of new drugs.
%20sales%20of%20the%20company%20Corcept%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Corcept-Therapeutics&v=1772623084890 "Schedule of future (projected) sales of the company Corcept Therapeutics")
Future (projected) sales of companies in the market segment - Pharma metabolism
Corcept Therapeutics focuses on developing drugs to treat metabolic and oncological diseases associated with the hormone cortisol. The company's success depends on clinical trial results and drug approvals. This chart displays projected sales for the entire metabolism-related pharmaceutical segment, demonstrating overall growth expectations in this therapeutic area.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-metabolism&v=1772623084963 "Schedule of future (projected) sales of companies in the market segment - Pharma metabolism")
Future (projected) sales of the market as a whole
Corcept Therapeutics develops drugs to treat metabolic and oncological diseases associated with the hormone cortisol. The company's success depends on investment in research and the market acceptance of its drugs. This graph reflects the overall economic situation, which impacts public and private healthcare budgets, and which affects the speed of commercialization of Corcept's developments.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772623085001 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Corcept Therapeutics
Corcept Therapeutics is focused on developing drugs that affect the hormone cortisol. This metric is a measure of its commercial success. It demonstrates what portion of the company's drug sales revenue remains as net profit after the company's massive R&D and marketing expenditures, which are critical for any pharmaceutical company.
Market segment marginality - Pharma metabolism
Corcept Therapeutics specializes in developing drugs to treat severe metabolic and oncological diseases. For a biopharmaceutical company with a narrow focus, profitability is a key indicator of success. The data in the chart demonstrates its operating efficiency compared to the industry, reflecting the commercial potential of its drugs and cost control.
Market marginality as a whole
Corcept Therapeutics develops drugs to treat metabolic and oncological diseases caused by the hormone cortisol. As a biotech company, their success is less dependent on general economic cycles. However, this overall profitability curve is important because it influences investors' appetite for risk and the funding of expensive clinical trials.
Employees in the company, segment and market as a whole
Number of employees in the company Corcept Therapeutics
Corcept Therapeutics develops drugs to treat severe metabolic and oncological diseases associated with the hormone cortisol. For the biopharmaceutical company, staffing is key to its scientific and commercial potential. This chart shows how the company is expanding its team to conduct clinical trials and bring new drugs to market.
Share of the company's employees Corcept Therapeutics within the market segment - Pharma metabolism
Corcept Therapeutics develops drugs to treat diseases associated with the hormone cortisol. This chart shows the proportion of highly specialized scientists and clinicians in the field of metabolic disorders that the company attracts. Its team is at the intellectual forefront in the fight against rare and complex diseases.
Number of employees in the market segment - Pharma metabolism
Corcept Therapeutics focuses on developing drugs that regulate the hormone cortisol for the treatment of metabolic and oncological diseases. This chart shows overall employment in the pharmaceutical sector. For a highly specialized company like Corcept, it illustrates the overall talent landscape in which it competes for top scientists and researchers.
Number of employees in the market as a whole
Corcept Therapeutics is focused on developing cortisol-regulating drugs for the treatment of rare diseases. This chart reflects the biotech company's development stages. The increase in staff, particularly in R&D and clinical trials, indicates progress in developing new drugs and advancing them toward commercialization.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Corcept Therapeutics (CORT)
For the biotech company Corcept Therapeutics, this chart shows that its entire value comes from its intellectual property. The company has no large manufacturing facilities; its market capitalization is based on patents for the drugs it develops. A small team of scientists and managers creates a product with enormous market value, which is reflected in its high index.
%20of%20the%20company%20Corcept%20Therapeutics%20(CORT)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Corcept-Therapeutics-CORT&v=1772623085315 "Chart of market capitalization per employee (in thousands of dollars) of the company Corcept Therapeutics (CORT)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma metabolism
Corcept Therapeutics is a pharmaceutical company focused on cortisol-regulating drugs (for example, for the treatment of Cushing's syndrome). Like other biotechs, it has an R&D-intensive IP business. This metric, compared to the industry average, reflects how highly the market values their patents and the potential per scientist.
%20by%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-metabolism&v=1772623085396 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma metabolism")
Market capitalization per employee (in thousands of dollars) for the overall market
Corcept Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of metabolic diseases. Its value is determined primarily by its intellectual property and the potential of its research drugs. The high valuation per employee reflects the research-intensive nature of the business, where a small team of scientists can create a blockbuster.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772623085405 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Corcept Therapeutics (CORT)
Corcept Therapeutics focuses on developing drugs to treat metabolic and oncological diseases associated with the hormone cortisol. As a biotech company, the company spends heavily on R&D. This chart shows how well these investments in science (in the form of scientists' salaries) translate into commercial success and net profit from the sale of approved drugs.
%20Chart%20Corcept%20Therapeutics%20(CORT)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Corcept-Therapeutics-CORT&v=1772623085580 "Company Profit Per Employee (in thousands of dollars) Chart Corcept Therapeutics (CORT)")
Profit per employee (in thousands of dollars) in the market segment - Pharma metabolism
Corcept is a biopharmaceutical company focused on Cushing's syndrome (Korlym). This chart shows the benchmark for "Pharma Metabolism." In this sector (orphan and rare diseases), employee profitability is exorbitant. Monopolistic companies in their niche set very high drug prices, which sets an astronomical benchmark.
%20in%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-metabolism&v=1772623085805 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma metabolism")
Profit per employee (in thousands of dollars) for the market as a whole
Corcept Therapeutics (CORT) is a biopharmaceutical company focused on developing cortisol-modulating drugs for the treatment of metabolic diseases and oncology. This graph, showing average profit per employee, is particularly important for biotech. It allows one to assess how much a sector where a handful of scientists can create a multi-billion-dollar drug outperforms the "average" labor efficiency.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772623085849 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Corcept Therapeutics (CORT)
At Corcept Therapeutics, a biopharmaceutical company, this chart illustrates the commercial success of its drugs. High revenue per employee speaks to the high value and demand for the drugs developed to treat metabolic disorders, as well as the effectiveness of a small but focused team.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Corcept-Therapeutics-CORT&v=1772623085880 "Sales chart per company employee Corcept Therapeutics (CORT)")
Sales per employee in the market segment - Pharma metabolism
Corcept Therapeutics is a biopharmaceutical company focused on cortisol-modulating drugs. In biotech, the efficiency of R&D and commercialization is critical. This metric measures the average revenue per employee in the segment. It helps assess how productive Corcept's team is in drug development and commercialization compared to other companies in the metabolic drug sector.
Sales per employee for the market as a whole
Corcept Therapeutics (CORT) is a biopharmaceutical company focused on treating diseases associated with the hormone cortisol. For a pharmaceutical company with an approved drug, this metric reflects commercial success. The growth in revenue per employee demonstrates how effectively their relatively small team (including R&D and sales) can generate revenue from their flagship product.
Short shares by company, segment and market as a whole
Shares shorted by company Corcept Therapeutics (CORT)
Corcept Therapeutics is a biopharmaceutical company whose success depends almost entirely on a single drug, Korlym, for the treatment of Cushing's syndrome. Such a high concentration is extremely risky. This chart illustrates investor concerns about potential competition, patent disputes, or failure to develop new drugs that could diversify revenue.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Corcept-Therapeutics-CORT&v=1772623086022 "Short Shares Chart for the Company Corcept Therapeutics (CORT)")
Shares shorted by market segment - Pharma metabolism
Corcept Therapeutics (CORT) focuses on developing drugs that modulate the stress hormone cortisol for the treatment of metabolic diseases and oncology. This chart shows the total short position in the metabolic pharmacology sector. It highlights the level of investor skepticism about the success of clinical trials or the market potential of this class of drugs.
Shares shorted by the overall market
Corcept Therapeutics (CORT) is a pharmaceutical company focused on treating cortisol-related disorders. When Short_All rises, it signals investor risk aversion. This pessimism is especially toxic for biotech companies, whose valuations depend on the future success of their drugs, not current profits. In times of fear, investors prefer safety.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Corcept Therapeutics (CORT)
Corcept Therapeutics focuses on cortisol-regulating drugs (for the treatment of Cushing's syndrome). Its business depends on the success of its key drug. A CORT reading above 70 may reflect strong sales or positive trial data. A reading below 30 is often associated with concerns about competition or R&D failures.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Corcept-Therapeutics-CORT&v=1772623086135 "RSI 14 indicator chart for the company's stock Corcept Therapeutics (CORT)")
RSI 14 Market Segment - Pharma metabolism
Corcept Therapeutics is a pharmaceutical company focused on treating metabolic disorders by modulating cortisol. Their lead drug treats Cushing's syndrome. This chart measures the overall momentum in the metabolism pharmaceutical sector. It helps determine whether the entire segment is overheating amid advances in obesity treatment.
RSI 14 for the overall market
Corcept Therapeutics focuses on cortisol-modulating drugs for the treatment of metabolic and oncological diseases. Like many pharmaceutical companies, CORT is less dependent on the general economic cycle. Market turmoil, as seen in this chart, may have less of an impact on demand for its drugs, as health is a priority, unaffected by investor euphoria.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CORT (Corcept Therapeutics)
Corcept Therapeutics is a biopharmaceutical company whose business is built around Korlym (mifepristone), a drug used to treat Cushing's syndrome. This chart shows the average 12-month target from analysts. It reflects their expectations for Korlym sales and, more importantly, the success of their R&D program to develop new, more selective modulators.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CORT-Corcept-Therapeutics&v=1772623086411 "A chart showing analyst consensus forecasts for the expected stock price. CORT (Corcept Therapeutics)")
The difference between the consensus estimate and the actual stock price CORT (Corcept Therapeutics)
Corcept Therapeutics (CORT) is a pharmaceutical company focused on treating metabolic and oncological diseases by modulating the hormone cortisol. This chart shows their R&D score. It measures the gap between the price and the consensus target, reflecting analysts' confidence in the success of their drugs, which target a complex hormonal mechanism.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CORT-Corcept-Therapeutics&v=1772623086442 "A chart showing the difference between the consensus forecast and the actual stock price. CORT (Corcept Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Pharma metabolism
Corcept Therapeutics is a biopharmaceutical company focused on developing drugs that regulate the hormone cortisol (used to treat Cushing's syndrome). This chart shows analysts' overall expectations for the entire metabolism sector. It reflects whether experts believe drug development in this complex niche is successful.
Analysts' consensus forecast for the overall market share price
Corcept Therapeutics is a single-product biotech focused on treating Cushing's syndrome (excess cortisol). Market expectations, as seen in this chart, have little impact on them. Their business is not the economy, but doctors' decisions and diagnoses. However, in a downturn (pessimism), payers (insurers) can exert greater pressure on prices.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Corcept Therapeutics
Corcept Therapeutics is a biopharmaceutical company focused on treating diseases related to the hormone cortisol. Their only commercial drug, Korlym, is targeted at patients with Cushing's syndrome. This graph reflects their monopoly position. Its dynamics depend on the growth of their flagship drug and the market's confidence in their R&D pipeline to develop new drugs using the same platform.
AKIMA Market Segment Index - Pharma metabolism
Corcept Therapeutics is a niche pharma company focused on cortisol-induced metabolic diseases; its key drug (Korlym) treats Cushing's syndrome. This summary metric measures R&D. The chart shows the segment average. This benchmark: how does Corcept's ultra-niche strategy (and its reliance on a single drug) differentiate it from the average pharma company?
The AKIM Index for the overall market
Corcept is a biotech company focused on a rare disease (Cushing's syndrome) associated with excess of the stress hormone cortisol. Its success is built on a single drug. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this scientific story, driven by the laws of biotech, compares to overall economic trends.
